Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar 18;20(3):565-75.
doi: 10.1021/bc8004914.

(S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics

Affiliations

(S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics

Gyula Tircsó et al. Bioconjug Chem. .

Abstract

A bifunctional version of PCTA (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9,-triacetic acid) that exhibits fast complexation kinetics with the trivalent lanthanide(III) ions was synthesized in reasonable yields starting from N,N',N''-tristosyl-(S)-2-(p-nitrobenzyl)-diethylenetriamine. pH-potentiometric studies showed that the basicities of p-nitrobenzyl-PCTA and the parent ligand PCTA were similar. The stability of M(NO(2)-Bn-PCTA) (M = Mg(2+), Ca(2+), Cu(2+), Zn(2+)) complexes was similar to that of the corresponding PCTA complexes, while the stability of Ln(3+) complexes of the bifunctional ligand is somewhat lower than that of PCTA chelates. The rate of complex formation of Ln(NO(2)-Bn-PCTA) complexes was found to be quite similar to that of PCTA, a ligand known to exhibit the fastest formation rates among all lanthanide macrocyclic ligand complexes studied to date. The acid-catalyzed decomplexation kinetic studies of the selected Ln(NO(2)-Bn-PCTA) complexes showed that the kinetic inertness of the complexes was comparable to that of Ln(DOTA) chelates making the bifunctional ligand NO(2)-Bn-PCTA suitable for labeling biological vectors with radioisotopes for nuclear medicine applications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DTPA and DOTA and two bifunctional derivatives commonly used in nuclear medicine.
Figure 2
Figure 2
Structure of NETA, AAZTA, PCTA and NO2-Bn-PCTA.
Figure 3
Figure 3
Absorbance changes in UV region during the formation of Ce(NO2-Bn-PCTA) after mixing Ce3+ and the ligand at 10:1 metal to ligand concentration ratio at pH=4.20 (in 0.04 M DMP, I=1.0 M KCl and CLig=6×10−5 M), the curves represent the UV-spectrum of 1) 40 mM buffer, 2) 6×10−4 M CeCl3 in DMP buffer, 3) 6×10−5 M ligand in DMP buffer, 4) immediately after mixing the Ce3+ with the ligand (“0” min), 5) after 2 min, 6) after 7 min, 7) after 12 min and 8) after 70 min (equilibrium).
Figure 4
Figure 4
Formation rates of Ce(NO2-Bn-PCTA) (blue diamonds), Eu(NO2-Bn-PCTA) (green triangles), Yb(NO2-Bn-PCTA) (purple circles) and Yb(PCTA) (red circles) vs. OH ion concentration (I=1.0 M KCl, t=25 °C).
Figure 5
Figure 5
Dependence of the dissociation rate constants (kd) on the H+ ion concentration in the dissociation of Ce(NO2-Bn-PCTA) (blue diamonds), Eu(NO2-Bn-PCTA) (green triangles), Yb(NO2-Bn-PCTA) (purple circles) complexes at 25°C.
Scheme 1
Scheme 1
Synthesis of the bifunctional ligand, NO2-Bn-PCTA.

Similar articles

Cited by

References

    1. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–778. - PMC - PubMed
    1. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38:358–366. - PMC - PubMed
    1. De Leon-Rodriguez LM, Kovacs Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjugate Chem. 2008;19:391–402. - PubMed
    1. Chong HS, Ma X, Le T, Kwamena B, Milenic DE, Brady ED, Song HA, Brechbiel MW. Rational design and generation of a bimodal bifunctional ligand for antibody - targeted radiation cancer therapy. J Med Chem. 2008;51:118–125. - PMC - PubMed
    1. Breeman WAP, de Blois E, Bakker WH, Krenning EP. Radionuclide peptide cancer therapy. In: Chinol M, Paganelli G, editors. Radionuclide Peptide Cancer Therapy. Taylor & Francis; New York: 2006. pp. 119–125.

Publication types

MeSH terms

Substances